How far should we go with cost-utility analysis when treating children with acute idiopathic thrombocytopenic purpura?
Benesch
Martin
M
D002648:Child; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D016527:Drug Costs; D004358:Drug Therapy / Q000191:economics; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use; D008775:Methylprednisolone / Q000191:economics / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000191:economics*
D016756:Immunoglobulins, Intravenous; D008775:Methylprednisolone